Christopher Martin

Xenva Ltd. provides boutique management services. The company was founded on June 19, 1997 and is headquartered in Hampshire, the United Kingdom.

Tokamak Energy Ltd. provides medical and biotechnology services. It develops the potential to use fusion neutrons for a variety of applications from material treatments to medical applications or low cost hydrogen production. The company was founded by David Richard Kingham, Mikhail Gryaznevich and Alan Sykes in 2009 and is headquartered in Abingdon, the United Kingdom.

Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France.

Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011.

Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom.

ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom.